Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
GLP-1 receptor agonists show liver benefits for older adults. A large retrospective study found that GLP-1 RA therapy in adults 65+ with metabolic liver disease (MASLD) was tied to significantly lower risks of liver decompensation, hospitalization, and death. However, higher rates of osteoporosis and retinopathy were also observed, and no cardiovascular benefit was seen.
GLP-1 receptor agonists — the drug class behind medications like semaglutide — may offer meaningful liver-related benefits for older adults battling metabolic dysfunction-associated steatotic liver disease (MASLD). A retrospective cohort study published in Age and Ageing analyzed over 87,000 patients aged 65 and older, comparing GLP-1 RA users to unexposed patients using propensity-score matching. The results showed that GLP-1 RA use was linked to meaningfully lower risks of hepatic decompensation, all-cause mortality, and hospitalization.
That said, the findings weren't entirely straightforward. Researchers flagged higher rates of osteoporosis (without fracture) and retinopathy among GLP-1 RA users, and no reduction in major adverse cardiovascular events — like heart attack or stroke — was observed. The study's authors are calling for randomized trials in older adults to better define who benefits most and who may need closer monitoring.
By the Numbers:
Why it matters: As GLP-1 RAs become increasingly mainstream, understanding their risk-benefit profile in older, more vulnerable populations is critical. This study adds important nuance — real liver and survival benefits exist, but clinicians should keep an eye on bone health and vision in elderly patients on these medications.
